Ultromics Enters into a Collaboration Agreement with Pfizer to Enhance the Development of EchoGo for the Detection of Cardiac Amyloidosis
Shots:
- Ultromics has signed an agreement with Pfizer to support the validation, development, and US FDA clearance for Ultromics’ AI-based technology, EchoGo for the detection of cardiac amyloidosis
- Under the terms of the agreement, Ultromics will be responsible for the research & regulatory clearance for EchoGo Amyloidosis algorithm. Moreover, the company’s technology leverages deep learning to analyse routine ultrasound scans of the heart (echocardiograms) to detect disease
- In Dec 2023, Ultromics was chosen to participate in the US FDA’s TAP Pilot as in Nov 2022, Ultromics received the US FDA’s BDD for EchoGo based on studies depicting the device’s ability to improve the detection of heart failure
Ref: Ultromics | Image: Ultromics
Related News:- Ultromics’ EchoGo Amyloidosis Receives the US FDA’s Breakthrough Device Designation to Detect Cardiac Amyloidosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
